[{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tris Pharma Inc \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Tris Pharma Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Tris Pharma Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Forest Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tris Pharma Inc \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Tris Pharma Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma Inc","highestDevelopmentStatusID":"8","companyTruncated":"Park Therapeutics \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Tris Pharma Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Forest Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Tris Pharma Inc \/ Forest Laboratories"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tris Pharma Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Tris Pharma Inc","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Tris Pharma Inc \/ National Institute on Drug Abuse"}]
Find Clinical Drug Pipeline Developments & Deals for Cebranopadol
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
